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EVALUATION OF THE ELISA-F29 TEST AS AN EARLY MARKER OF THERAPEUTIC EFFICACY IN 
ADULTS WITH CHRONIC CHAGAS DISEASE
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SUMMARY
This work compared the time at which negative seroconversion was detected by conventional serology (CS) and by the ELISA-F29 
test on a cohort of chronic chagasic patients treated with nifurtimox or benznidazole. A retrospective study was performed using 
preserved serum from 66 asymptomatic chagasic adults under clinical supervision, and bi-annual serological examinations over a mean 
follow-up of 23 years. Twenty nine patients received trypanocide treatment and 37 remained untreated. The ELISA-F29 test used a 
recombinant antigen which was obtained by expressing the Trypanosoma cruzi flagellar calcium-binding protein gene in Escherichia 
coli. Among the untreated patients, 36 maintained CS titers. One patient showed a doubtful serology in some check-ups. ELISA-F29 
showed constant reactivity in 35 out of 37 patients and was negative for the patient with fluctuating CS. The treated patients were 
divided into three groups according to the CS titers: in 13 they became negative; in 12 they decreased and in four they remained 
unchanged. ELISA-F29 was negative for the first two groups. The time at which negativization was detected was significantly lower 
for the ELISA-F29 test than for CS, 14.5 ± 5.7 and 22 ± 4.9 years respectively. Negative seroconversion was observed in treated 
patients only. The results obtained confirm that the ELISA-F29 test is useful as an early indicator of negative seroconversion in treated 
chronic patients.
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INTRODUCTION
American trypanosomiasis or Chagas disease, caused by the parasite 
Trypanosoma cruzi, is endemic in 21 countries of Central and South 
America. The Pan American Health Organization (PAHO) estimates that 
7.7 million people currently have T. cruzi infection and 50,000 patients 
die every year due to Chagas disease17.
Although the infection is mainly transmitted by vectors, there are 
other transmission routes such as blood transfusions, organ transplants 
or through the placenta.
Human Chagas disease begins with an acute phase that appears 
just after a generally asymptomatic infection or with scarce symptoms. 
Without treatment, most infected persons evolve to a symptomless chronic 
period in which they stay for the rest of their life. However, several 
years after infection about 30% of these people will present clinical 
evidence of disease with different degrees of cardiac affection and/or 
gastrointestinal affection.
Trypanocidal drugs, nifurtimox and benznidazole, are recommended 
for treatment during both the acute and the early chronic phases (children 
under 15 years old), and for patients who present a risk of reactivation 
of the latent infection with T. cruzi due to immunosuppression (patients 
with AIDS and those receiving post-transplant immunosuppressive drugs, 
or under oncologic treatment).
Both drugs often have side effects that may be worse in older people. 
Moreover, the existence of naturally resistant T. cruzi strains has been 
demonstrated in experimental models12,16,23.
Studies carried out on adult persons with chronic T. cruzi infection 
have shown great differences in the trypanocidal effectiveness and in 
the progression towards chronic chagasic cardiopathy (CCC)3,4,6,8,11,24.
The evaluation of etiological treatment of adults with chronic T. cruzi 
infection presents several difficulties, such as the slow natural evolution 
of the disease and a lack of parasitological and serological tests that can 
indicate the efficacy of trypanocidal drugs at an early stage.
Circulating parasites are scarce in the chronic phase. Parasitological 
tests (xenodiagnosis, hemoculture) are only meaningful when they are 
positive, indicating a therapeutic failure.
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Nowadays, conventional serology (CS) is the main tool for the 
primary diagnosis of this infection in the chronic phase. Therefore, the 
accepted criterion of cure after treatment is the persistent absence of 
anti-T. cruzi antibodies as measured by CS5.
The parasites are extremely antigenic and produce a strong antibody 
response that persists even after complete deparasitation. The progressive 
decrease in titers usually takes years or decades until serology becomes 
negative. This diminution occurs more slowly in adults than in children.
Many serological techniques have been evaluated as possible cure 
markers1,13,14,15. Furthermore, there has been an increase in the use of 
molecular methods for detecting T. cruzi in blood samples of treated 
patients4,7,19,20.
During the 1990s, two randomized clinical trials in children with 
chronic T. cruzi infection treated with benznidazole were performed using 
non-conventional serological methods (AT ELISA and ELISA-F29) as 
cure markers. The results showed the safety and efficacy of this drug, as 
it produced negative seroconversion in 55.8% and 62% of the patients, 
three and four years after treatment respectively2,21. Our group performed 
a longitudinal study in chronic chagasic children younger than 14 years 
of age treated with nifurtimox or benznidazole. Although it is difficult 
to compare the results from different methods, we observed a similar 
percentage of negativization according to CS, but after a follow-up 
period of 14 years22.
On the other hand, we previously reported the results of a transversal 
study performed on sera from chronic chagasic patients treated with 
nifurtimox or benznidazole, which sought to evaluate the recombinant 
protein F29 as a possible marker of treatment efficacy. There was a 
correlation between CS and ELISA-F29 for treated patients who showed 
negativization in CS and for non-treated patients, but no treated patients 
remained reactive to CS9.
The aim of the present work was to compare the time at which 
negative seroconversion is detected in both tests, ELISA-F29 and CS, 
in a cohort of adult patients with chronic T. cruzi infection both treated 
and untreated (control group) with trypanocidal drugs.
MATERIALS AND METHODS
This retrospective study was carried out on 66 adult patients with 
chronic infection by T. cruzi who were voluntarily attending the Centre 
for Research in National Endemic Diseases for check-ups, during a 
mean follow-up of 23 years. The Centre is located within the School 
of Biochemical Sciences, Littoral National University, Santa Fe City, 
Argentina.
The participants were selected according to their current residence 
(Santa Fe City, Argentina) and age (17 to 46 years old). They were 
informed about the study and those who gave their consent to participate 
in it were included in the follow-up. This protocol was approved by the 
Ethics Committee of the School of Biochemistry and Biological Sciences.
Patients were controlled every two years by means of clinical 
examination, 12-lead resting electrocardiogram (ECG) and serological 
studies of venous blood samples.
CS tests included direct agglutination (DA), indirect hemagglutination 
(IHA), indirect immunofluorescence (IIF) and ELISA, with whole 
homogenate of T. cruzi. Sera with positive reactions to all tests were 
considered positive (≥ 1/32 titers for the first three reactions). Serum 
samples obtained from the different serological check-ups were preserved 
at -20 ºC and/or glycerinated.
The criterion for negative seroconversion was the persistent 
negativization of all previously positive tests. A “decrease in serum 
titers” was considered when the number dropped in two or more dilutions 
of serum without reaching negative seroconversion, “inconclusive 
serology” when some tests were reactive to 1/32 titers and others were 
non-reactive, and finally “fluctuating serology” when CS tests showed 
reactivity in some serological checks and not in others.
Before 1983 trypanocide treatment was administered to symptomless 
infected individuals who had given their consent to be treated. Depending 
on the availability of drugs, patients were given nifurtimox (8-10 mg/
kg/day over 45-60 days) or benznidazole (5 mg/kg/day over 30 days, 
with half of the dose in the first week). None of the cases were pregnant 
women or patients with associated severe diseases (systemic infections 
with cardiac, respiratory, renal or hepatic insufficiency). Procedures 
were in accordance with the ethical standards of the National Ministry 
of Health, Argentina.
Chosen individuals (n = 66) were those who attended regularly for 
controls with well preserved serum samples. Twenty nine symptomless 
patients received trypanocide treatment (nifurtimox = 16; benznidazole 
= 13) and 37 remained untreated.
F29 Antigen: The F29 gene (GenBank accession number: Z54193.1) 
was originally cloned into the pMalp2X expression vector18. In order to 
increase the amount of expressed protein and to avoid the cleavage step 
of the fusion protein, the F29 gene was subcloned into the pQE32 vector. 
The gene was amplified using the forward primer F29 (5’-ATG GGT 
GCT TGT GGG TCG AA-3 ‘) and the reverse primer F29 (5’-TCA AGC 
CTT CTC CGG CAC GT -3´). The PCR reaction was performed using 
Pfu polymerase, and finally the amplified fragment was cloned into the 
Sma I site of expression vector pQE32 (Qiagen). The 6His - F29 protein 
was expressed and purified using a column of nickel-nitrilotriacetic acid 
agarose (Qiagen) under native conditions following the manufacturer’s 
protocol.
ELISA-F29: An ELISA test using the F29 protein of T. cruzi was 
performed on 211 serums collected at different times during the follow-
up of 66 patients, distributed as follows: A) 108 samples belonged to 29 
patients treated with trypanocidal drugs. Only five of them had serum 
samples before the specific treatment. For the rest, the lack of available 
samples in a good state of conservation was no reason to exclude patients, 
due to the limited number of infected persons undergoing treatment. For 
nine patients the first sample analyzed was taken between one and four 
years post-treatment; for the remaining 15, the first analysis was carried 
out on sera that had been collected at a mean time of 11 years after the 
treatment had finished, B) 103 serum from 37 untreated patients.
The conservation status of sera was previously evaluated through CS. 
Those sera that preserved the antibody level observed in fresh serum at 
the moment of serological check-up were selected.
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Cut-off value ELISA-F29 = 0.198
Statistical analysis: Student’s t-test, Mann Whitney U test, binomial 
test, Kaplan-Meier curves, log-rank test and GEE (Generalized 
Estimating Equations) were used as was appropriate. A p value of < 0.05 
was considered significant.
RESULTS
The people in both groups of patients infected with T. cruzi, those 
treated with trypanocidal drugs and those who remained untreated, were 
of similar age, sex and follow-up period (Table 1).
Treated patients (n = 29) were grouped according to the serological 
evolution of CS during the follow-up as follows: (i) 13 had negative 
seroconversion; (ii) 12 presented a significant decrease of titers or 
inconclusive serology, while (iii) four remained reactive and conserved 
the serological titers.
Table 2 shows the results of ELISA-F29 during the follow-up, in 
relation to the serological evolution of CS in the treated patients. 
As can be seen in the table, final reactivity of the ELISA-F29 test was 
observed in 2/29 (6.9%) of the patients undergoing specific treatment. 
In 10/29 patients the ELISA-F29 test did not detect Ac anti-F29, all 
the analyzed samples being post-treatment. Negative seroconversion 
according to the ELISA-F29 test was observed in 17/19 (89.4%) of 
infected patients treated, while according to CS this happened only in 
13/29 (44.8%) of them. These proportions differ significantly (p < 0.05, 
binomial test).
Because of the conservation status of sera, pre-treatment samples 
were not available from all patients. In fact, the first sample analyzed 
corresponded to a different time for each one of the patients, both before 
and after treatment. 
The relationship between the time when the first available sample 
was analyzed and the reactivity of ELISA-F29 is detailed in Table 3. As 
the time elapsed since the completion treatment increased, the reactivity 
of the sample decreased (p < 0.05, binomial test).
Using the GEE model, which includes all measurements of anti-F29 
antibodies from each patient during the follow-up, a significant fall of 
these antibodies due to treatment was observed (p << 0.05; measure of 
OD drop = 0.177).
The average time for negative seroconversion was 14.5 ± 5.7 years for 
ELISA-F29 and 22 ± 4.9 years for CS. These differences were statistically 
significant (p = 0.0004, Student’s t-test).
Table 1
Patients with chronic Chagas disease, treated with trypanocidal drugs and untreated, distributed according to age groups, sex and length of follow-up
Age§ group 
(years)
Treated Untreated
Sex F/M Total Years of follow-up (mean ± SD) Sex F/M Total
Years of follow-up 
(mean ± SD)
17 to 26 5/3a 8 23.6 ± 3.8b 8/4a 12 23.3 ± 5.7b
27 to 36 12/3a 15 22.2 ± 3.0b 13/4a 17 23.6 ± 2.5b
37 to 46 5/1a 6 21.3 ± 5.6b 5/3a 8 22.9 ± 4.2b
Total 22/7 29  26/11 37
§ Age at the time of inclusion; a: the proportion of men and women was similar between treated and untreated patients, p > 0.05 binomial test; b: there were no significant 
differences in the length of follow-up between treated and untreated patients, p > 0.05 Student’s test. 
Table 2
Serological evolution of CS and ELISA-F29 for the group of treated patients
CS 
 ELISA-F29
Total
Constant (-) Negative se-
roconversion Constant (+)
i - Negative 
seroconver-
sion
5 8 0 13
ii - Decreased 
titres or 
inconclusive 
serology
4 8 0 12
iii - Constant 
titres (+)
1 1 2 4
Total 10 17 2 29
CS: conventional serology.
Table 3
Percentage of positivity of ELISA-F29 on the first sample analyzed according 
to the time that passed since finalizing the treatment
Time of the first sample 
analyzed
ELISA-F29
n Positivity %
Pre-treatment 5 5 100
Post-treatment
≤ 4 years 9 7 77.7
> 4 years 15 5 33.3
p < 0.05, binomial test.
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The probability of negative seroconversion (proportion of reactive 
patients during the follow-up) according to CS or ELISA-F29 was 
evaluated using the Kaplan-Meier curves (Fig. 1).
When using the log-rank test for comparing both curves, a very 
significant difference (p << 0.05) was observed.
50% of treated patients presented negativization 16 years after 
treatment, according to the ELISA-F29 test, while according to CS this 
happened 26 years post-treatment.
The age of the patients at the time at which they received trypanocide 
treatment was considered. The relation between the age at which infected 
patients were treated and the probability of negative seroconversion 
according to CS and ELISA-F29 was not statistically relevant among 
the three age groups (p > 0.05, log-rank test).
No significant differences were observed when the probability of 
negative seroconversion according to CS was analyzed with respect to 
the drug used in the treatment – nifurtimox or benznidazole- (p = 0.73). 
The same thing happened for the ELISA-F29 test (p = 0.59).
Among the untreated patients (n = 37), the initial CS titers remained 
constant during the follow-up in 36 of them and only one presented 
fluctuating serology in some check-ups.
The ELISA-F29 test was reactive in 94.6% (35/37) of them; no 
changes in reactivity were seen throughout the follow-up. No F29 
antibodies were detected in the only patient whose CS fluctuated.
In the untreated patients group, no negative seroconversion was 
observed in any of the tests (CS and ELISA-F29).
DISCUSSION
In previous publications10,11 our group showed results of an evaluation 
of a specific antiparasitic treatment in adults with chronic infection by 
Trypanosoma cruzi, with an average follow-up of 23 years.
Before treatment, 94.7% of the patients had positive xenodiagnosis. 
Post-treatment, three xenodiagnoses per patient were performed, all of 
which were negative.
Accompanying these results, persistent negative seroconversion 
according to CS in at least 45.5% of patients treated with nifurtimox 
or benznidazole was observed. The average time of serological 
negativization was 19 years post-treatment.
With regard to clinical evolution, 3.64% of the treated patients and 
17.54% of the untreated ones showed disturbances on electrocardiograms 
during the follow-up period, attributable to Chagas disease. This 
difference is statistically significant (p < 0.05).
These results coincide with those of other researchers who have 
used the same doses and period for benznidazole administration (5mg/
kg/day over 30 days)24,25.
These studies demonstrate the effectiveness of the trypanocidal 
treatment after a period of 15 years. The required prolonged time of 
follow-up constitutes the main difficulty for the therapeutic evaluation in 
infected chronic patients. In the present work the times at which negative 
seroconversion was detected by ELISA-F29 were significantly smaller 
than the ones observed for CS.
The percentage of treated patients who did not present reactivity for 
ELISA-F29 was high. It is important to highlight that the majority of 
the serum samples analyzed were collected after treatment because of 
the conservation status. Pre-treatment samples (n = 5) in good condition 
for analysis were 100% positive.
In the group of nontreated patients, 94.6% of them were persistently 
positive for the ELISA-F29 test. It is expected that a similar percentage 
of reactivity occurs in serum samples obtained before the therapeutic 
intervention.
Furthermore, the anti-F29 antibody evolution significantly decreased 
due to the effect of the treatment when all sera belonging to each patient 
were analyzed, with a DO decrease of 0.177 among samples. This 
decrease is close to the cut-off value (0.198).
Despite limitations of sensitivity that are frequently present in 
recombinant techniques that use Ag of a single band, only negative 
seroconversion was observed in the patients that received treatment, 
which together with the fall in the level of anti-F29 reactivity would 
indicate a diminution of the parasitic load at least.
In the final follow-up, the reactivity of the ELISA-F29 test to sera 
from treated patients was 6.9%. This finding led us to presume that 
the treatment was able to eliminate all parasites in 93.1% of infected 
individuals. 
It is necessary to continue with the follow-up of patients whose 
CS is positive and ELISA-F29 negative, in order to corroborate this 
presumption.
The results of the ELISA-F29 test for untreated patients showed no 
negative seroconversion for anyone in this group. As for the patients 
Fig. 1 - Kaplan Meier curve demonstrating the proportion of reactivity over time by CS and 
ELISA-F29 in treated chronic chagasic patients.
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who did not present anti-F29 antibodies (2/37), it is necessary to carry 
out complementary studies such as the Western blot analysis and PCR, 
in order to define this discrepancy.
The probability of negative seroconversion according to CS and 
ELISA-F29 had no connection with the age at which infected adults 
received treatment. These findings are different to those observed in 
children with chronic infection, since the lower the age of the treated 
patients, the higher the probability of negativization22.
This paper presents the advantage of using serum samples collected 
at different periods of time over long term supervision. This situation 
allowed for the observance of the persistent negativization of CS tests, 
which is the gold standard for cure. When ELISA-F29 and CS tests were 
evaluated in parallel, the mean time for negative seroconversion was 
significantly different (p << 0.05, log-rank test). 
In conclusion, our results demonstrate that the ELISA-F29 test 
significantly anticipated negative seroconversion compared to CS. 
Consequently, the ELISA-F29 test can be used as a complementary test 
in the therapeutic evaluation.
The ELISA-F29 test has the advantage of not requiring much 
infrastructure, since it is a fast serological test with a simple procedure.
RESUMO
Avaliação do tratamento tripanossomicida em coorte de adultos 
chagásicos crônicos através de técnicas sorológicas convencionais 
e ELISA-F29
Este trabalho comparou os tempos de soroconversão negativos obtidos 
pela sorologia convencional (CS) e teste ELISA-F29 em uma coorte de 
pacientes chagásicos crônicos tratados com nifurtimox ou benznidazol. 
Um estudo retrospectivo foi realizado com soro preservado de 66 adultos 
chagásicos assintomáticos com acompanhamento clínico e sorológico 
semestral ao longo de um seguimento médio de 23 anos. 29 pacientes 
receberam tratamento tripanossomicida e 37 outras permaneceram sem 
tratamento. O teste ELISA-F29 usou um antígeno recombinante obtido 
por expressão do gene de uma proteína flagelar de Trypanosoma cruzi de 
ligação de cálcio em Escherichia coli. Entre os pacientes não tratados, 36 
mantiveram os títulos da CS. Um paciente apresentou sorologia duvidosa 
em alguns controles. ELISA-F29 apresentou reatividade constante em 
35/37 e foi negativo no paciente com CS flutuante. Os pacientes tratados 
foram agrupados de acordo com os títulos da CS, em três grupos: 13 
tornaram-se negativos, 12 diminuíram e quatro permaneceram inalterados. 
ELISA-F29 foi negativo nos dois primeiros grupos. O tempo de 
negativização foi significativamente menor para o teste ELISA-F29 do que 
para CS (14,5 ± 5,7 e 22 ± 4,9 anos, respectivamente). A soroconversão 
negativa foi observada somente nos pacientes tratados. Os resultados 
obtidos confirmam que o teste ELISA-F29 é útil como um indicador 
precoce de soronegativação em pacientes crônicos tratados.
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